HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Data Supplement Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takahashi, Y. Articles by Kanazawa, I. Search for Related Content PubMed PubMed Citation Articles by Takahashi, Y. Articles by Kanazawa, I. Related Collections All Immunology Autoimmune diseases Peripheral neuropathy All Clinical trials Clinical trials Observational study (Cohort, Case control)

Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren’s syndrome

From the Department of Neurology (Drs. Takahashi, Takata, Hoshino, Sakurai, and Kanazawa), Graduate School of Medicine, University of Tokyo; Department of Geriatric Medicine (Dr. Takata), School of Medicine, University of Kobe, Hyogo; and Department of Physiology (Dr. Sakurai), Teikyo University School of Medicine, Tokyo, Japan.

Address correspondence and reprint requests to Dr. Yuji Takahashi, Department of Neurology, Graduate School of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655, Japan; e-mail address: takahashiy-int{at}h.u-tokyo.ac.jp

Ataxic sensory neuronopathy with Sjögren’s syndrome is a devastating neurologic complication for which there is no established treatment. IV immunoglobulin (IVIG) was given to five patients with severe disabilities for an average of 12 years. Four patients showed remarkable improvement, two of whom responded after the first course. The authors conclude that IVIG is safe and effective to treat even chronically debilitated patients who have the disease, presumably because it ameliorates smoldering inflammation.

This article has been cited by other articles:

				M Kizawa, K Mori, M Iijima, H Koike, N Hattori, and G Sobue Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjogren's syndrome. J. Neurol. Neurosurg. Psychiatry, August 1, 2006; 77(8): 967 - 969. [Abstract] [Full Text] [PDF]

				K. Mori, M. Iijima, H. Koike, N. Hattori, F. Tanaka, H. Watanabe, M. Katsuno, A. Fujita, I. Aiba, A. Ogata, et al. The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy Brain, November 1, 2005; 128(11): 2518 - 2534. [Abstract] [Full Text] [PDF]

				S Yamada, K Mori, K Matsuo, A Inukai, Y Kawagashira, and G Sobue Interferon alfa treatment for Sjogren's syndrome associated neuropathy J. Neurol. Neurosurg. Psychiatry, April 1, 2005; 76(4): 576 - 578. [Abstract] [Full Text] [PDF]

				T. M. Burns, S. Quijano-Roy, H. R. Jones, G. I. Wolfe, S. P. Nations, D. K. Burns, L. L. Herbelin, R. J. Barohn, Y. Takahashi, M. Sakurai, et al. Benefit of IVIg for long-standing ataxic sensory neuronopathy with Sjogren's syndrome Neurology, September 23, 2003; 61(6): 873 - 873. [Full Text] [PDF]

				IVIG: Effective Treatment for Sensory Neuronopathy in Sjogren's? Journal Watch Neurology, May 9, 2003; 2003(509): 7 - 7. [Full Text]

Correspondence: